|
1
|
Salerno F, Guevara M, Bernardi M, Moreau
R, Wong F, Angeli P, Garcia-Tsao G and Lee SS: Refractory ascites:
Pathogenesis, definition and therapy of a severe complication in
patients with cirrhosis. Liver Int. 30:937–947. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arroyo V, Ginès P, Gerbes AL, Dudley FJ,
Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H and Schölmerich J:
Definition and diagnostic criteria of refractory ascites and
hepatorenal syndrome in cirrhosis. International Ascites Club.
Hepatology. 23:164–176. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyer TD: Tolvaptan and hyponatremia in a
patient with cirrhosis. Hepatology. 51:699–702. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okita K, Kawazoe S, Hasebe C, Kajimura K,
Kaneko A, Okada M and Sakaida I: ASCITES Dose-Finding Trial Group:
Dose-finding trial of tolvaptan in liver cirrhosis patients with
hepatic edema: A randomized, double-blind, placebo-controlled
trial. Hepatol Res. 44:83–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schrier RW, Gross P, Gheorghiade M, Berl
T, Verbalis JG, Czerwiec FS and Orlandi C: SALT Investigators:
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for
hyponatremia. N Engl J Med. 355:2099–2112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okita K, Sakaida I, Okada M, Kaneko A,
Chayama K, Kato M, Sata M, Yoshihara H, Ono N and Murawaki Y: A
multicenter, open-label, dose-ranging study to exploratively
evaluate the efficacy, safety and dose-response of tolvaptan in
patients with decompensated liver cirrhosis. J Gastroenterol.
45:979–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakaida I, Kawazoe S, Kajimura K, Saito T,
Okuse C, Takaguchi K, Okada M and Okita K: ASCITES-DOUBLEBLIND
Study Group: Tolvaptan for improvement of hepatic edema: A phase 3,
multicenter, randomized, double-blind, placebo-controlled trial.
Hepatol Res. 44:73–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dahl E, Gluud LL, Kimer N and Krag A:
Meta-analysis: The safety and efficacy of vaptans (tolvaptan,
satavaptan and lixivaptan) in cirrhosis with ascites or
hyponatraemia. Aliment Pharmacol Ther. 36:619–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Leveen HH, Christoudias G, Ip M, Luft R,
Falk G and Grosberg S: Peritoneo-venous shunting for ascites. Ann
Surg. 180:580–591. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Martin LG: Percutaneous placement and
management of peritoneovenous shunts. Semin Intervent Radiol.
29:129–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ginès P, Arroyo V, Vargas V, et al:
Paracentesis with intravenous infusion of albumin as compared with
peritoneovenous shunting in cirrhosis with refractory ascites. N
Engl J Med. 325:829–835. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nitta H, Okamura S, Mizumoto T, et al:
Prognosis assessment of patients with refractory ascites treated
with a peritoneovenous shunt. Hepatogastroenterology. 60:1607–1610.
2013.PubMed/NCBI
|
|
13
|
Miyaaki H, Murakami E, Ichikawa T, et al:
Long-term increase in liver volume after Denver peritoneovenous
shunt: Report of two cases. Liver Int. 29:774–775. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Onishi Y, Wakita T, Fukuhara S, et al:
Development and validation of a symptom scale specific for ascites
accompanied with cirrhosis: The ASI-7. Clin Transl Gastroenterol.
5:e482014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heuman DM, Abou-Assi SG, Habib A, Williams
LM, Stravitz RT, Sanyal AJ, Fisher RA and Mihas AA: Persistent
ascites and low serum sodium identify patients with cirrhosis and
low MELD scores who are at high risk for early death. Hepatology.
40:802–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Girleanu I, Stanciu C, Cojocariu C, et al:
Natural course of nonmalignant partial portal vein thrombosis in
cirrhotic patients. Saudi J Gastroenterol. 20:288–292. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawaguchi T, Shiraishi K, Ito T, et al:
Branched-chain amino acids prevent hepatocarcinogenesis and prolong
survival of patients with cirrhosis. Clin Gastroenterol Hepatol.
12:1012–1018.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nahon P, Lescat M, Layese R, et al:
Bacterial infection in compensated viral cirrhosis impairs 5-year
survival (ANRS CO12 CirVir prospective cohort). Gut:
gutjnl-2015-310275. 2015.(Epub ahead of print). View Article : Google Scholar
|
|
19
|
Arvaniti V, D'Amico G, Fede G, Manousou P,
Tsochatzis E, Pleguezuelo M and Burroughs AK: Infections in
patients with cirrhosis increase mortality four-fold and should be
used in determining prognosis. Gastroenterology. 139:1246–1256.
2010. View Article : Google Scholar : PubMed/NCBI
|
